Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide (NVO:NYSE)

Novo Nordisk shares sink as CagriSema misses tirzepatide weight-loss goal in phase 3.

You are being redirected to the original discussion. Please continue if you want to read the full post.

Continue to original article

You will be redirected in 3 seconds.